

Supplementary Table 2. Patient characteristics associated with flare during the randomised withdrawal-retreatment period of COAST-Y.

Variable	Category	Odds ratio (95% CI)	p-value
Categorical			
Treatment ^a	Placebo (N=53), IXE (N=102)	5.51 (2.68,11.33)	<0.001
Sustained low CRP	Yes (N=136), No (N=19)	0.40 (0.15,1.05)	0.063
BMI group at week 0 of COAST-Y	Non-normal (N=86), normal (N=69)	1.81 (0.93,3.52)	0.081
Residual inflammation by MRI at Week 24 of COAST-Y	Yes (N=55), No (N=84)	1.79 (0.89,3.60)	0.101
Geographic region	Non-Europe (N=97), Europe (N=58)	1.63 (0.82,3.23)	0.165
Length of IXE treatment at week 24 of COAST-Y	24-60 weeks (N=69), 76 weeks (N=86)	1.51 (0.79,2.90)	0.215
Tobacco use group	Ever (N=63), Never (N=92)	0.89 (0.46,1.73)	0.741
Concomitant DMARD use at Week 0 of COAST-Y	Yes (N=63), No (N=92)	1.41 (0.73,2.72)	0.310
CRP group at week 24 of COAST-Y	>5 mg/L (N=22), ≤5 mg/L (N=133)	1.43 (0.57,3.55)	0.442
Anti-drug antibody positive at any time between Week 0 of the originating study and Week 24 of COAST-Y	Yes (N=32), No (N=123)	1.35 (0.61,2.97)	0.458
HLA-B27 at baseline of originating study	Positive (N=137), negative (N=18)	0.74 (0.27,2.00)	0.554
Age group at Week 0 of COAST-Y	≥35 years (N=88), <35 years (N=67)	1.18 (0.61,2.28)	0.616
Prior TNFi experience	Yes (N=26), No (N=129)	1.24 (0.53,2.91)	0.626
Symptom duration group at Week 0 of COAST-Y	≥10 years (N=85), <10 years (N=70)	0.86 (0.45,1.65)	0.653
Tobacco use group	Current (N=45), Former/Never (N=110)	1.12 (0.55,2.28)	0.751
CRP group at baseline of originating study	>5 mg/L (N=96), ≤5 mg/L (N=59)	1.05 (0.54,2.06)	0.876
Anti-drug antibody positive at Week 24 of COAST-Y	Yes (N=10), No (N=143)	1.10 (0.30,4.07)	0.888
Symptom duration group at Week 0 of COAST-Y	≥5 years (N=123), <5 years (N=32)	1.03 (0.46,2.30)	0.941
Sex	Male (N=116), Female (N=39)	0.98 (0.46,2.06)	0.953
AxSpA classification	r-axSpA (N=97), nr-axSpA (N=58)	1.01 (0.52,1.97)	0.979
Continuous			
ASDAS area under the curve ^b	Continuous	1.06 (1.01,1.11)	0.021
CRP at baseline of originating study	Continuous	1.02 (1.00,1.04)	0.037
ASDAS at week 24 of COAST-Y	Continuous	2.09 (1.02,4.27)	0.044
Total back pain at Week 24 of COAST-Y	Continuous	1.26 (1.00,1.60)	0.050
BASDAI inflammation at Week 24 of COAST-Y	Continuous	1.31 (0.95,1.79)	0.095
PatGA at Week 24 of COAST-Y	Continuous	1.21 (0.95,1.54)	0.123
BASDAI at Week 24 of COAST-Y	Continuous	1.25 (0.93,1.69)	0.144
ASDAS at baseline of originating study	Continuous	1.24 (0.85,1.82)	0.257
BASFI at Week 24 of COAST-Y	Continuous	1.16 (0.88,1.54)	0.284
CRP at Week 24 of COAST-Y	Continuous	1.05 (0.94,1.18)	0.353
CRP area under curve ^b	Continuous	1.00 (1.00,1.01)	0.365
BASFI at baseline of originating study	Continuous	1.05 (0.90,1.23)	0.542
Total back pain at baseline of originating study	Continuous	1.04 (0.85,1.27)	0.699
BASDAI at baseline of originating study	Continuous	1.04 (0.83,1.28)	0.752
BASDAI inflammation at baseline of originating study	Continuous	0.98 (0.82,1.17)	0.809
PatGA at baseline of originating study	Continuous	1.02 (0.84,1.23)	0.856

^aTreatment group (placebo or IXE) at the start of the randomized withdrawal period at week 24 of COAST-Y, ^bArea under the curve for ASDAS and CRP are defined as the area under the curve across time from weeks 0 to 24 in COAST-Y. Abbreviations: ASDAS, Ankylosing Spondylitis Disease Activity Score; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; IXE, ixekizumab.